SAGE Journals Online
Advertisement
Sign In to gain access to subscriptions and/or personal tools.

 

Advanced Search

Journal Navigation

Journal Home

Subscriptions

Archive

Contact Us

Table of Contents

Advertisement

Sign In to gain access to subscriptions and/or personal tools.
Lupus
This Article
Right arrow Full Text (PDF)
Right arrow References
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to Saved Citations
Right arrow Download to citation manager
Right arrowRequest Permissions
Right arrow Request Reprints
Right arrow Add to My Marked Citations
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Web of Science (9)
Right arrow Citing Articles via Google Scholar
Right arrow Citing Articles via Scopus
Google Scholar
Right arrow Articles by DeBandt, M
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by DeBandt, M
Social Bookmarking
Add to CiteULike   Add to Complore   Add to Connotea   Add to Del.icio.us   Add to Digg   Add to Reddit   Add to Technorati   Add to Twitter  
What's this?

Lessons for lupus from tumour necrosis factor blockade

M DeBandt

Rheumatology Department, Hôpital Robert Ballanger, Aulnay sous Bois, 93600, France m.debandt{at}ch-aulnay.fr

Systemic lupus erythematosus (SLE) is a systemic non-organ specific autoimmune disease associated with multiple autoantibodies targeting autoantigens from the nucleus. Given the complex pathophysiology of SLE and the role of TNF alpha in that disease, modulation of TNF alpha (in SLE or non-SLE patients) using TNF blockers could either be detrimental or beneficial in some patients. In this review we will focus on lupus autoantibodies and clinical manifestations after TNF blockade in SLE patients and conversely on drug-induced-SLE in non-SLE patients. Some hypotheses regarding the mechanism of induction of autoantibodies in RA patients treated with TNF blockers are proposed.

Key Words: drug-inducedlupus • systemiclupuserythematosus • TNFblockers • tumournecrosisfactor(TNF)

Lupus, Vol. 15, No. 11, 762-767 (2006)
DOI: 10.1177/0961203306071703
Add to CiteULike CiteULike   Add to Complore Complore   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us   Add to Digg Digg   Add to Reddit Reddit   Add to Technorati Technorati   Add to Twitter Twitter    What's this?


This article has been cited by other articles:


Home page
 Mayo Clin Proc.Home page
D. A. Wetter and M. D. P. Davis
Lupus-Like Syndrome Attributable to Anti--Tumor Necrosis Factor {alpha} Therapy in 14 Patients During an 8-Year Period at Mayo Clinic
Mayo Clin. Proc., November 1, 2009; 84(11): 979 - 984.
[Abstract] [Full Text] [PDF]

Home page
 LupusHome page
K. Su, S. Tsai, S. Tsay, H. Lee, W. Chen, and D. Huang
A patient with systemic lupus erythematosus and Crohn's disease complicated with massive lower gastrointestinal bleeding, mimicking intestinal vasculitis
Lupus, November 1, 2008; 17(11): 1049 - 1050.
[PDF]


Advertisement